I'll read the brief first.

I've read the brief in full. Summary of what I'm executing:

- **Step 1**: Independent `scientific-reviewer` pass scoped to the three corrections (4A gnomAD constraint cross-reference; 4E mixed-effects re-analysis; 4C fibroblast-testability framing), verified against the primary-source quotes you supplied, with a grep check for any residual "immune-hot" language.
- **Step 2**: CSO finalization — `ERRATA_figure4_corrections.md`, new claim objects in `evidence/claims.json` (append-only), final `panel_by_paper_comparison.md` + `FINAL_REPORT.md`, cost/timing, and exact deliverable paths. I will read from CORR/round-2 and write into my own new run directory. No analysis re-run.

Let me load the run-organization skill (required before delegation) and survey the run directories.

Skill loaded. Now let me read the corrected deliverables and the round-2 claims schema before dispatching the reviewer.

The corrected comparison document reads coherently. Now let me read the three correction reports/tables and the round-2 claims schema.

I've read the three correction reports, the corrected comparison document, and the round-2 claims schema (C101–C118; the correction doc references C120–C124, which are not yet filed — that's the Step 2 gap). Let me set up tracking and run the mechanical "immune-hot" sweep plus read the round-2 baseline for the errata.

Mechanical sweep result: every "immune-hot" occurrence in the CORR run is in *correction context* (the corrected panel doc at lines 10/90/148, the corrected 4E report at 26/236 and the revised source report at 14/22/740) — no file still asserts immune-hot as the paper's claim. The round-2 baseline (run `76d40ca3`) did assert it (panel doc §4E line 74, FINAL_REPORT lines 39/49), so the errata has a clear factual basis.

Now recording the plan and reading the data tables the reviewer will check.

Tables cross-check against the report text on first pass (e.g., T-cell β −0.01642 / low mean 0.5094 = −3.22%; depth medians 7,545.0 vs 3,708.5 = 2.03×; n = 13,886 = 6,943/6,943; 12 sections / 5 donors). Now dispatching the scoped scientific review.

Review verdict in: **ACCEPT WITH DISCLOSED LIMITATIONS**, no blocking scientific findings, but four editorial fixes and two wording refinements. Before applying anything I'll verify the flagged p-values and contrast counts directly against the tables.

Review is detailed and evidence-backed. I'll independently verify the three flagged p-values and the DE contrast labeling before applying fixes.

All three flagged p-values and the 11-primary/4-paired split are confirmed against the raw CSV, fit log, and DE table:
- depth+fibroblast macrophage: **1.98e-6** (report says 2e-7)
- complete-ring T: **2.52e-6** (report says 2e-8); macrophage: **1.81e-5** (report says 2e-6)
- DE table: 11 `primary_all_donors` + 4 `paired_3donors` = 15; three blank padj rows all p > 0.05.

I'll run one focused revision round to stage corrected specialist artifacts into this run (no re-analysis), then a targeted re-confirmation. First, let me inspect this run's scaffolding.

Reviewer verdict is confirmed at the artifact level. Now executing the single focused editorial/staging round (no re-analysis): correcting the three transcribed p-values and staging the verified artifacts into this run.

Staging and the three p-value corrections are complete and byte-verified. Now producing the corrected final panel document, then dispatching the targeted re-confirmation.

All six fixes are RESOLVED with no new defects. Now finalizing: errata, claims registration, and final report.

I had read the brief in full, and both remaining steps are now complete.

## Review verdict

**ACCEPT WITH DISCLOSED LIMITATIONS**, with no blocking scientific error. The independent reviewer confirmed:

- all four primary-source quotes are reproduced verbatim;
- the 4E model is implemented exactly as specified (neighbour-mean response, own-spot depth/fibroblast/malignant fixed effects, section random intercept, REML, BH across 9 types), with 108/108 sensitivity fits converged and every reported coefficient/CI/q matching the CSV[[claim:C136]];
- the 4A cross-reference is exact and correctly bounded as gene-level constraint, not disease association[[claim:C130]];
- the 4C census decision is justified and honestly framed as untestable, not refuted[[claim:C134]][[claim:C135]].

The reviewer found three **transcribed p-values** in the 4E sensitivity table that overstated significance by 10–100×, one omitted caveat, and two wording imprecisions.

## Was a revision needed?

**No full revision and no re-analysis.** One focused editorial round was applied: the three p-values were corrected by direct substitution from the sensitivity CSV/fit log (`2e-7→2.0e-6`, `2e-8→2.5e-6`, `2e-6→1.8e-5`; two lines, three tokens, coefficients/CIs unchanged), and the comparison document gained the random-effect-boundary and rank-fallback caveats plus corrected 4B/4C labels. A targeted re-confirmation found **F7, F8, F9, F11, F12 and F17 all RESOLVED, with no new defects**[[claim:C136]].

## Final deliverables

Run root: `/mnt/beegfs/xqinag/projects/TheVirtualBiotech/runs/20261022-120126-this-continues-a-targeted-correc-06b840ce`

- `report/ERRATA_figure4_corrections.md` — standalone traceable errata
- `report/panel_by_paper_comparison.md` — final reviewed comparison
- `report/FINAL_REPORT.md` — final report
- `evidence/claims.json` — 10 new claims (C130–C139), 24/24 evidence verified; round-2 claims untouched
- `report/archive/round2_delivery/` — verbatim round-2 documents preserved (history not overwritten)
- `work/scientific-reviewer/results/reports/review_correction_pass.md`
- `work/scientific-reviewer/results/reports/review_reconfirmation_corrections.md`
- `work/single-cell-analyst/results/tables/` — 4E primary/sensitivity/group-construction, 4C donor counts/DE summary/testability
- `work/single-cell-analyst/results/reports/` — corrected 4E report, fit log, 4C census check
- `work/single-cell-analyst/code/scripts/visium_correction_mixed_effects_4e.py`
- `work/genomics-analyst/results/{tables,reports}/` — 4A constraint cross-reference

## Cost and timing

Run wall-clock ≈ 19 minutes. SDK-reported dispatches: staging/4E fix 46,862 tokens / 176 s; 4A staging 34,817 / 134 s; re-confirmation review 91,409 / 121 s. No `logs/cost_report.json` was emitted during the run, so no billing total is available.

**Suggested next steps:**
1. **Freeze and cite this run** — C130–C139 are your citable anchors; the archived round-2 copies make the correction audit-complete.
2. **Resolve the 4E random-effect limitation** — a donor-level or sample-level random effect with more sections would test whether the section-RE boundary affects the 8/9 result.
3. **Close the fibroblast gap prospectively** — a matched LUAD/normal study with ≥3 normal fibroblast donors is the only way to test the paper's 4C claim directly.

Would you like me to pursue any of these?